Researcher
Dominique Schols
- Disciplines:Microbiology, Systems biology, Laboratory medicine
Affiliations
- Laboratory of Virology and Chemotherapy (Rega Institute) (Division)
Responsible
From1 Jan 2014 → Today - Laboratory of Virology and Chemotherapy (Rega Institute) (Division)
Member
From1 Oct 1999 → Today
Projects
1 - 10 of 29
- Validation of CCR8 agonism as therapeutic strategy for treatment of (auto-)inflammationFrom1 Mar 2024 → TodayFunding: IOF - technology validation in lab
- Real-time, label-free analysis of extracellular vesicles and their proteins using surface plasmon resonance technologyFrom29 Aug 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- The viral G protein-coupled receptor ORF74: Expanding the toolbox to better understand receptor signaling, function and pharmacologyFrom22 Sep 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Elucidation of the mechanism of action of novel HTLV-1 inhibitors: a step-by-step approachFrom21 Sep 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Development and preclinical evaluation of diagnostic and therapeutic radiopharmaceuticals targeting CXCR4From10 Aug 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Development of allosteric intracellular modulators attenuating chemokine receptor CCR5 signallingFrom1 May 2021 → TodayFunding: BOF - doctoral mandates
- A novel class of reversible Exportin-1 inhibitors for cancer therapyFrom1 Jan 2021 → 31 Dec 2022Funding: IOF - technology validation in lab
- Design and synthesis of next-generation C-C chemokine receptor type 5 antagonists.From28 Jul 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Intravital microscopy platform for infectious and inflammatory diseasesFrom1 May 2020 → TodayFunding: FWO Medium Size Research Infrastructure
- Discovery of CCR7 small molecule inhibitors by virtual screening andhit-to-lead optimization.From1 Oct 2019 → 30 Sep 2021Funding: BOF - projects
Publications
41 - 50 of 371
- Anthranilamides with quinoline and β-carboline scaffolds: design, synthesis, and biological activity(2022)
Authors: Dirk Daelemans, Dominique Schols
Pages: 2595 - 2612 - Innate lymphoid cells are required to induce airway hyperreactivity in a murine neutrophilic asthma model (vol 13, 849155, 2022)(2022)
Authors: Anne-Charlotte Jonckheere, Sven Seys, Brecht Steelant, Jonathan Cremer, Dominique Schols, Greetje Vande Velde, Christine Breynaert, Rik Schrijvers, Jeroen Vanoirbeek, Jan Ceuppens, et al.
- Triphosphate Prodrugs of the Anti-HIV-Active Compound 3′-Deoxy-3′-fluorothymidine (FLT)(2022)
Authors: Dominique Schols
Pages: 12163 - 12175 - Carbohydrate-binding protein from stinging nettle as fusion inhibitor for SARS-CoV-2 variants of concern(2022)
Authors: Emiel Vanhulle, Sam Noppen, Dominique Schols, Annelies Stevaert, Kurt Vermeire
- Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model(2022)
Authors: Maya Imbrechts, Wim Maes, Louanne Ampofo, Nathalie Van den Berghe, Bas Calcoen, Winnie Kerstens, Madina Rasulova, Sam Noppen, Rana Abdelnabi, Piet Maes, et al.
- Cellular Electrical Impedance as a Method to Decipher CCR7 Signalling and Biased Agonism(2022)
Authors: Katrijn Boon, Dominique Schols, Tom Van Loy
- The discovery of Zika virus NS2B-NS3 inhibitors with antiviral activity via an integrated virtual screening approach(2022)
Authors: Steven De Jonghe, Dominique Schols, Mathy Froeyen
- Cryo-EM structures of wild-type and E138K/M184I mutant HIV-1 RT/DNA complexed with inhibitors doravirine and rilpivirine(2022)
Authors: Abhi Singh, Dominique Schols, Piet Herdewyn, Christophe Pannecouque, Kalyan Das
- In-Depth Characterization of Zika Virus Inhibitors Using Cell-Based Electrical Impedance(2022)
Authors: Merel Oeyen, Dominique Schols
- Organotropic dendrons with high potency as HIV-1, HIV-2 and EV-A71 cell entry inhibitors(2022)
Authors: Rana Abdelnabi, Sam Noppen, Johan Neyts, Dominique Schols
Patents
1 - 6 of 6
- Isoquinoline and pyridine based cxcr4 antagonists (Inventor)
- Prodrugs of nucleoside phosphonates (Inventor)
- Novel prodrugs of nucleoside phosphonates (Inventor)
- Prodrugs of fluorinated acyclic nucleoside phosphonates (Inventor)
- Prodrugs of fluorinated acyclic nucleoside phosphonates (Inventor)
- Novel prodrugs of nucleoside phosphonates (Inventor)